Glenmark Pharmaceuticals (NSE:GLENMARK) Research & Development: ₹0 Mil (TTM As of Mar. 2026)


NSE:GLENMARK Glenmark Pharmaceuticals Ltd NSE:GLENMARK
85 GF Score
Price ₹2,161.90
GF Value ₹1,985.75
Valuation Fairly Valued
View Full Analysis

What is Glenmark Pharmaceuticals Research & Development?

Glenmark Pharmaceuticals NSE:GLENMARK -1.92% 85 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:GLENMARK with a GF Score™ of 85/100 and a GF Value™ of ₹1,985.75 (Fairly Valued).

Research & Development is the aggregate amount of research and development expenses during the year. Glenmark Pharmaceuticals's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Glenmark Pharmaceuticals  (NSE:GLENMARK) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Glenmark Pharmaceuticals Research & Development Related Terms

Glenmark Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Glenmark Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glenmark Pharmaceuticals Research & Development Chart

Glenmark Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Glenmark Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:GLENMARK
85GF Score
Glenmark Pharmaceuticals Ltd NSE:GLENMARK
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glenmark Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Glenmark Pharmaceuticals (NSE:GLENMARK) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Glenmark Pharmaceuticals and its competitors.
Is Glenmark Pharmaceuticals' Research & Development too high?
Glenmark Pharmaceuticals' current Research & Development is ₹0 Mil. Overall, Glenmark Pharmaceuticals has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Glenmark Pharmaceuticals' Research & Development compare to ZTS and UTHR?
Glenmark Pharmaceuticals' Research & Development of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Glenmark Pharmaceuticals and its competitors. Glenmark Pharmaceuticals's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glenmark Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals (NSE:GLENMARK) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,985.75, compared to a current price of ₹2,161.90 — trading 8.9% above its estimated fair value. The current Research & Development is ₹0 Mil. Glenmark Pharmaceuticals' overall GF Score™ is 85/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Glenmark Pharmaceuticals (NSE:GLENMARK), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Overvalued in 2026?

Based on GuruFocus' analysis, Glenmark Pharmaceuticals stock appears to be overvalued. The current stock price of ₹2,161.90 is trading 8.9% above its estimated GF Value™ of ₹1,985.75. GuruFocus considers Glenmark Pharmaceuticals to be Fairly Valued.

Key valuation signals for NSE:GLENMARK:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹1,985.75 vs. price of ₹2,161.90 (8.9% above fair value)
  • GF Score™: 85/100

No single metric tells the full story. See the NSE:GLENMARK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Glenmark Pharmaceuticals Business Description

Other Exchanges 532296:India
Address B. D. Sawant Marg, Glenmark House, Chakala, Off Western Express Highway, Andheri (East), Mumbai, MH, IND, 400099
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.
85GF Score

Get the complete analysis for NSE:GLENMARK

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,161.90
Price
₹1,985.75
GF Value